It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Vistagen Therapeutics Inc (VTGN) Common Stock USD0.001

Sell:$2.13 Buy:$2.14 Change: $0.20 (8.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.20 (8.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.20 (8.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Contact details

343 Allerton Ave
United States
+1 (650) 5773600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$337.23 million
Shares in issue:
141.69 million
United States
US dollar

Key personnel

  • Jon Saxe
    Independent Chairman of the Board
  • H. Ralph Snodgrass
    President, Founder, Chief Scientific Officer, Director
  • Shawn Singh
    Chief Executive Officer, Director
  • Jerrold Dotson
    Chief Financial Officer, Vice President, Secretary
  • Mark Ginski
    Senior Vice President, Head of CMC (Chemistry, Manufacturing and Controls)
  • Mark McPartland
    Vice President - Corporate Development
  • Louis Monti-Bloch
    Vice President
  • Ann Cunningham
    Chief Commercial Officer, Director
  • Mark Smith
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.